PDF-Measles Prevention and Exposure Guidance for Healthcare PersonnelHealt

facility considers it cost effective For who have 2 documented doses of measlesand mumpscontaining vaccine and 1 documented dose of rubellacontaining vaccine or other acceptable evidence of measles. Tenth Annual  Measles Initiative Meeting . September 13-14, 2011 Washington, DC. Sergei Deshevoi. WHO European Region . 2. Presentation outline. Regional goal and strategy. Progress towards goal. Challenges in reaching the goal in 2015. Panel 01502. Vicki Stambos. The 13. th. Global Measles and Rubella Laboratory Network Meeting, Geneva, Switzerland, 29. th. June to 1. st. July 2015. Vicki Stambos. Accelerating Progress Towards Measles and Rubella Control and Elimination Meeting. Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Accelerating progress towards measles and rubella elimination. Geneva, Switzerland 21-23 June 2016 . Jenny Rota, WHO consultant. Goal is to update information to reflect current responsibilities of the network, provide best practices, resources and guidelines. Dr. Kimberly M. Thompson. Kid Risk, Inc., www.kidrisk.org. Topics. Context. I. ntegrated dynamic disease and economic . modeling. Discussion. http://www.wpro.who.int/vietnam/topics/immunization/measles_rubella/measles_rubella_big.png?ua=1. M&RI Partners’ Meeting. Michael F Thomas, . Director Vaccine Implementation. September 2017, Washington DC. Page: . 1. Reach every child. . Measles and Rubella support in Gavi countries by end of 2016. Dr. Khin Devi Aung. Gavi Secretariat. 21. . June 2016, Geneva. 1. #. vaccineswork. AGENDA. About Gavi, the Vaccine Alliance. Gavi’s. support to countries. Gavi’s. 2016-2020 Strategy. Gavi’s. 2020. . Summary of the . Findings . and Implementation Status . Dr Kaushik . Banerjee. M&RI Partners' Meeting. Washington DC. 7 September 2017. 1. Objectives . of . the Review. To provide a candid review of progress . Dr. Kimberly M. Thompson. Kid Risk, Inc., www.kidrisk.org. Topics. Context. I. ntegrated dynamic disease and economic . modeling. Discussion. http://www.wpro.who.int/vietnam/topics/immunization/measles_rubella/measles_rubella_big.png?ua=1. Donald McLaren, MD.   . Seventh International Symposium in Continuing Nursing Education/March 2014. Goals of talk. To highlight measles as a still very important major cause of under 5 mortality in the developing world and discuss diagnosis, complications and treatment. Measles. Etiology/agent factor . paramyxovirus.. morbillivirus. it is spherical in appearance ,measuring about 100~150nm in diameter . It has an outer envelope composed of M-protein, H-protein, F-protein, and internal core is RNA.. Measles Signs and Symptoms Prodrome ( fever AND cough or coryza or conjunctivitis ) lasting 2 - 4 days followed by rash . F eve (Assistant Professor, Pediatric Infectious Diseases). Dr. Jennifer Johnson MD, FAAP . (Director, Division of Urgent Care). For the Urgent Care Provider. Children’s Mercy Kansas City. September 5. th. Exposure: Leg pain on walking, outcome: knee pain. Exposure: knee pain, outcome: . M15 . Polyarthrosis. Exposure: . M15 . Polyarthrosis. . , outcome: knee pain. Exposure: knee pain, outcome: . other specific joint derangements.